Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down Syndrome

Q: What type of study is this?

This is a Cross-Sectional Study study.

Jason K Russell; Zinayida Schlachetzki; Beau Ances; Michael S. Rafii; Beau Ances; Howard F Andrews; Karen Bell; Rasmus M Birn; Adam M Brickman; Jeff Burns; J M Burns; Amrita K. Cheema; Kewei W. Chen; Bradley T Christian; Isabel C. H. Clare; Ann D Cohen; Eric W Doran; Tatiana M Foroud; Benjamin L Handen; J Harp; Sigan L Hartley; Elizabeth Head; Denise Head; Christy L. Hom; Lawrence Honig; Miloš D. Ikonomović; Sterling C Johnson; M. Ilyas Kamboh; David Keator; Julia Kofler; William Charles Kreisl; Sharon J Krinsky-McHale; Florence Lai; Patrick Lao; Charles M. Laymon; Joseph Hyungwoo Lee; Ira T Lott; Victoria Lupson; Mark Mapstone; Davneet Singh Minhas; Neelesh Nadkarni; Sid O'Bryant; Deborah Pang; Melissa Peterson; Julie C Price; Lauren Ptomey; Margaret Pulsifer; Michael S. Rafii; H. Diana Rosas; Frederick Schmitt; Nicole Schupf; Wayne Silverman; Dana L Tudorascu; Rameshwari Tumuluru; Badri Varadarajan; Michael A Yassa; Shahid Zaman; Fan Zhang

doi:10.1001/jamaneurol.2025.5261

January 12, 2026JAMA Neurology

Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down Syndrome

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to assess the concordance between biological and clinical staging of Alzheimer disease in individuals with Down syndrome.
Cross-sectional study design
Data from Alzheimer Biomarker Consortium–Down Syndrome study
Participants with Down syndrome examined for Alzheimer disease staging
Clinical and biological Alzheimer disease staging shows concordance
Identified biomarkers associated with disease progression in down syndrome

Implication

Cross-sectional analysis shows concordance of clinical and biological staging in Down syndrome, indicating the role of biomarkers.

Abstract

This cross-sectional study examines data for participants in the Alzheimer Biomarker Consortium–Down Syndrome study to gauge the concordance of clinical and biological Alzheimer disease staging.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Russell et al. (2026) studied this question.

synapsesocial.com/papers/6966e73513bf7a6f02bffc0d https://doi.org/10.1001/jamaneurol.2025.5261

View at Publisher

Ask AI

Bookmark

Share

Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down Syndrome

Key Points

Implication

Abstract

Discussion

Cite This Study

Concordance of Biological and Clinical Staging of Alzheimer Disease Pathology in Down Syndrome

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading